Pioneering precision medicines for high-need CNS disorders Two lead programs: an ASO for sporadic and genetic ALS patients targeting lipid biology, and an oral small molecule for schizophrenia targeting glutamate biology Lead programs on track for INDs this year, with clinical data in 2025 Additional pipeline programs in Alzheimer’s disease, epilepsy, and depression Pipeline Program […]
Investors 1
Mentions in press and media 1
| Date | Title | Description |
| - | Leal Therapeutics | “Pioneering precision medicines for high-need CNS disorders Two lead programs: an ASO for sporadic and genetic ALS patients targeting lipid biology, and an oral small molecule for schizophrenia targeting glutamate biology Lead programs on t... |
Reviews 0
